News About: Pharm. Industry
9 products suspended from health insurance benefits for provision of approx. KRW 2.6 billion rebates
Novartis’ 9 rebated drugs will be suspended from the health insurance benefits.
When it came to Novartis Korea’s issue about provision of rebates, the Ministry of Health and Welfare(MOHW) announced on the 27th that i...
“In regards to the support of the pharmaceutical and biotechnology fields, Korean drugs should be preferentially treated”
At a meeting with the National Health Insurance Service and Health Insurance Review & Assessment Service journalists on the 26th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) Chairman Hee-Mok W...
Unlisted pharmas’s profitability continues to improve with 10.1% operating profit ratio
Mid- and small-sized pharmaceutical companies’ profitability has continuously been improved.
This is because their operating profits, an index to assess earnings from business activities, was observed to narrowly inc...
Unlisted pharmas receive excellent sales report card
Unlisted pharmaceutical companies, most of them are relying on selling generic products, were observed to receive an excellent report card for their business last year.
Their sales were increased by more than 10% and...
Yuhan Corporation expands business into dental fieldYuhan Corporation(CEO Jung-Hee Lee) will expand the business into the dental field by acquiring Warantec, one of the Korean dental implant manufacturers.
Yuhan Corporation beca...
|
Multinational pharmas generates annual KRW 784 million sales per employee
Korean pharmaceutical companies branching in Korea were observed to generate KRW 784 million sales and KRW 173 million operating profits per employee last year.
According to the Yakup Shinmoon’s(www.yakup.com) analys...
Health insurance benefits for MSD Korea’s ‘Zepatier’ from this May
‘Zepatier,’ a MSD Korea’s chronic hepatitis C treatment, will be applied for the health insurance system from the 1st of May.
MSD Korea(CEO Avi BenShoshan) announced on the 25th at a press conference that the health ...
It takes 87 days to collect receivables for multinational pharmas
Multinational pharmaceutical companies were observed to take average 87 days to collect receivables after selling their pharmaceutical products. The length was 20 days shorter than 109 days that it takes on Korean lis...
Multinational pharmas pay about KRW 80 million for annual salary per employee
It was observed the average annual salary per employee working at multinational pharmaceutical companies’ Korean branches was close to KRW 80 billion, and employees working at GlaxoSmithKline and Sanofi Pasteur earned...
Foreign pharmas earn KRW 21 out of selling products worth of KRW 1,000 in Korean market
Korean branches of multinational pharmaceutical company were analyzed to earn KRW 21 out of selling products worth of KRW 1,000 last year.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2016 audi...
